• Methoxy-X04 and the Next Era of Amyloid Beta Imaging in AD

  2026-05-10

  Explore how Methoxy-X04, a fluorescent amyloid beta probe, is transforming Alzheimer’s disease research through high-affinity, in vivo imaging. This article uniquely connects molecular imaging to emerging therapeutic insights, advancing beyond workflow guides.

• Applied Workflows with (-)-Epigallocatechin Gallate (EGCG)

  2026-05-09

  Unlock the full potential of (-)-Epigallocatechin gallate (EGCG) in advanced tissue engineering, apoptosis assays, and cancer chemoprevention. This article translates recent breakthroughs—like EGCG’s sustained release in 3D bone scaffolds—into actionable protocols, troubleshooting insights, and optimization tips for reproducible research.

• Rucaparib (AG-014699): Applied PARP1 Inhibition in DDR Resea

  2026-05-09

  Rucaparib (AG-014699) delivers precise PARP1 inhibition for advanced DNA damage response assays, enabling robust radiosensitization and mechanistic insights in cancer biology research. This guide translates latest findings into practical workflows, protocol parameters, and troubleshooting strategies for reproducible results.

• Norovirus Exploits NINJ1 for Selective Protein Secretion Pat

  2026-05-08

  This study reveals that murine norovirus (MNoV) hijacks the cell death effector NINJ1 to enable selective secretion of the viral NS1 protein, identifying a non-canonical pathway for protein export during infection. These findings advance our understanding of virus-host interactions and programmed cell death, with broad implications for apoptosis regulation and biomarker release.

• Biotin-tyramide: Protocols and Troubleshooting for TSA

  2026-05-07

  Biotin-tyramide is a specialized biotin phenol reagent for tyramide signal amplification (TSA) in immunohistochemistry (IHC) and in situ hybridization (ISH), enabling high-resolution detection of low-abundance targets. It is not intended for diagnostic or medical use and is best avoided in workflows requiring aqueous solubility or extended solution storage.

• Latrunculin A: Mechanistic Power for Translational Actin Res

  2026-05-07

  This thought-leadership article explores Latrunculin A’s role as a reversible inhibitor of actin assembly, fusing mechanistic insight and practical strategy for translational researchers. It uniquely bridges tumor cell biology with emergent antiviral applications, referencing the latest proteomic evidence and optimized workflow guidance. The discussion advances beyond standard product literature, equipping scientists with knowledge and protocols for robust, reproducible, and innovative cytoskeleton disaggregation studies.

• Sulfaphenazole: Precision CYP2C9 Inhibitor for Vascular Rese

  2026-05-06

  Sulfaphenazole stands apart as a highly selective CYP2C9 inhibitor that enables rigorous control over oxidative stress and vascular function in preclinical models. Its dual role in modulating drug metabolism and improving tissue perfusion makes it indispensable for translational workflows targeting ischemia-reperfusion injury and drug-drug interaction studies.

• Phenothiazines Drive Macrophage Defense via ROS and Autophag

  2026-05-06

  This study demonstrates that phenothiazines, including promethazine hydrochloride, significantly augment the antibacterial activity of macrophages by inducing reactive oxygen species (ROS) production and autophagy. These findings provide mechanistic insight into host-directed strategies for combating intracellular pathogens and suggest new directions for inflammation and immunometabolism research.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-05

  Schwartz’s dissertation advances the evaluation of anti-cancer drug responses by distinguishing between proliferative arrest and cell death using separate quantitative metrics. This approach reveals nuanced drug effects and informs more precise experimental design in preclinical oncology research.

• STING Agonist-1: Translational Strategies for B Cell-Driven

  2026-05-05

  This thought-leadership article explores the mechanistic and strategic frontiers of STING pathway activation in translational immunology, with a focus on the role of STING agonist-1 in modeling tertiary lymphoid structure (TLS) biology and B cell activation. We integrate recent discoveries on the competitive interplay of CD40 and STING with TRAF2 in esophageal squamous cell carcinoma, offer actionable guidance for experimental design, and situate these advances in the context of the broader immunotherapy research landscape.

• APEX2 Regulates TERT Expression in Human Embryonic Stem Cell

  2026-05-04

  This study identifies apurinic/apyrimidinic endodeoxyribonuclease 2 (APEX2) as a previously unrecognized regulator of TERT expression in human embryonic stem cells and melanoma cells. The findings reveal a mechanistic link between DNA repair at repetitive elements and telomerase regulation, suggesting new avenues for understanding stem cell maintenance and cancer biology.

• GSK343: Selective EZH2 Inhibitor for Epigenetic Cancer Resea

  2026-05-04

  GSK343 is a potent and selective EZH2 inhibitor supplied by APExBIO. It enables precise inhibition of histone H3K27 trimethylation, facilitating targeted studies in cancer epigenetics. Its nanomolar potency and selectivity profile make it a benchmark tool for dissecting PRC2-mediated gene regulation.

• O-GlcNAcylation Regulates Ferroptosis in Preeclampsia via HU

  2026-05-03

  This study reveals that O-GlcNAc modification stabilizes HUWE1 to promote ubiquitination and degradation of the transferrin receptor (TfR1), thereby limiting iron uptake and suppressing ferroptosis in trophoblasts. Restoration of O-GlcNAcylation in preeclamptic models ameliorates syncytialization defects and adverse pregnancy outcomes, highlighting a novel mechanistic axis and therapeutic target for preeclampsia.

• N1-Methyl-Pseudouridine-5'-Triphosphate: Optimizing mRNA Wor

  2026-05-02

  N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP) elevates in vitro transcription by dramatically enhancing RNA stability and translational fidelity. This article translates breakthrough findings into actionable workflows, troubleshooting guidance, and advanced applications for researchers driving the next generation of mRNA therapeutics and vaccines.

• Toremifene in Breast Cancer: 20 Years of Clinical Insights

  2026-05-02

  This review synthesizes two decades of clinical data on toremifene, a selective estrogen receptor modulator (SERM), in the treatment of hormone-sensitive breast cancer. It highlights key methodological approaches, comparative findings with other endocrine therapies, and the evolving place of SERMs and aromatase inhibition in personalized oncology.

456 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page